On June 4 2026, a study appeared in the journal Cell. Scientists from The Francis Crick Institute, University College London and other centers found blood proteins that seemed to forecast lung cancer five years before symptoms emerged. They also suggested that the monoclonal antibody Canakinumab, which blocks interleukin-1 beta, could lower risk for people showing this protein pattern, based on a later review of an earlier trial.
These claims drew wide media coverage, prompting many to think a simple blood test could forecast lung cancer and a drug could stop it. Yet medical studies resist such broad summaries. Closer examination of the evidence and its limits is required.
The drug Canakinumab is an anti-inflammatory injection used for some forms of arthritis. Earlier investigators tested whether it could cut future heart problems in patients who had suffered a heart attack. The CANTOS trial, published in 2017, enrolled more than 10,000 such patients with raised inflammation markers. Participants received one of three doses or a placebo.
The trial focused on heart outcomes. After roughly four years, those given the drug experienced fewer heart events but also more fatal infections, a known risk tied to reduced immune defense.
A later analysis, not part of the original plan, noted fewer lung cancer diagnoses among those receiving Canakinumab. This observation prompted further work on whether blocking interleukin-1 beta might slow cancer development. However, the trial did not include routine lung scans, so some cancers may have gone undetected or been present before the study began. Without systematic screening, the true incidence in each group remains unclear.
The recent Cell paper reanalyzes CANTOS data and assumes the cancer reduction was real. It then seeks a biological basis using UK Biobank samples. Machine-learning methods identified a 14-protein pattern linked to later lung cancer. The authors link this pattern to an altered lung environment, yet the finding has not been confirmed in other studies nine years after the original trial.
